
Sign up to save your podcasts
Or
This week, a novel drug that reverses ticagrelor’s effect looks promising, a new certification process for cardiologists is unveiled, intensive blood pressure monitoring may not help prevent a second stroke, and the FDA cautions against using paclitaxel coated devices.
4.9
1616 ratings
This week, a novel drug that reverses ticagrelor’s effect looks promising, a new certification process for cardiologists is unveiled, intensive blood pressure monitoring may not help prevent a second stroke, and the FDA cautions against using paclitaxel coated devices.